Partner Content | 05 January 2022 | Influencers
Plasmid DNA as a starting material for large-scale mRNA vaccines from the PlasmidFactory
You have been working in plasmid research and production for 20 years and were immediately ava...Read more
Singapore | 07 October 2021 | Opinion
"The future of patient care could potentially be on a completely remote basis"
BioSpectrum Asia spoke to Benjamin Low, Vice-President, Asia Pacific, Milestone Systems, on how Singapore and ...Read more
Japan | 19 January 2022 | News
IQVIA releases emerging biotech/biopharma trends to watch for in 2022
IQVIA has come up with the key trends that emerging biotech and emerging biopharma companies should look out f...Read more
India | 19 January 2022 | News
Indian pharma major Lupin inks partnership agreement with Foncoo for China
India-based Lupin has entered into a partnership with Shenzhen Foncoo Pharmaceutical Co Ltd (Foncoo). This is ...Read more
Australia | 19 January 2022 | News
Australia to launch first collaborative cardiovascular research accelerator
Federal Minister for Health, Greg Hunt has announced funding for two new Research Centres through the MTPConne...Read more
Singapore | 17 January 2022 | News
Singapore deepens interest in dengue virus transmission
Software-analysed high-resolution videos have revealed that dengue-infected mosquitos are more attracted to ma...Read more
Singapore | 24 January 2022 | News
Singapore explores use of wearables to help detect depression
A team of scientists from Nanyang Technological University, Singapore (NTU Singapore) has developed a predicti...Read more
China | 19 January 2022 | News
China approves world's first artificial cornea of 100% non-biological materials
MIOK Keratoprosthesis has been approved for listing by National Medical Products Administration (NMPA), the Ch...Read more
China | 24 January 2022 | News
WuXi STA launches first parenteral formulation manufacturing line in China
WuXi STA, a subsidiary of WuXi AppTec, has announced that its first parenteral formulation manufacturing ...Read more
Korea | 11 January 2022 | News
South Korea-based SK Inc. invests $350 M in ‘Centre for Breakthrough Medicines’
The Centre for Breakthrough Medicines (CBM), based in the US, has received $350 million in equity financing fr...Read more
DIGITAL RESET
Nothing could have prepared the world for the unprecedented chain of events over the past two years. We prefaced 2020 and 2021 saying anything is possible, but no one saw this level of hyper volatility completely disrupting business and life as we know it. While the world is now firmly planted in a digital-format, the economic and business outlook for 2022 will remain highly fluid owing to the pandemic. Moreover, it is indeed very likely that in 2022, the majority of Asia Pacific’s GDP will be coming from digital products, services, and experiences across industries, with life sciences being one of them.
For Feedback Email Us : communications@biospectrumasia.com
1 North Bridge Road,
#08-08 High Street Centre,
Singapore 179094
Email : communications@biospectrumasia.com
